The laparoscopic power morcellator — the Tool That Spread Hidden Uterine Cancer

When Johnson & Johnson’s Ethicon division suspended global sales of its Gynecare power morcellators in April 2014 and recalled them outright that July, the gap between the device’s promise and its harm was already written into the abdomen of the woman who had forced the action: Dr. Amy Reed, a 40-year-old Boston anesthesiologist and mother of six, had undergone a laparoscopic hysterectomy at Brigham and Women’s Hospital in October 2013 to remove presumed-benign fibroids. The morcellator — a powered tube with a rotating blade that minces tissue for extraction through keyhole incisions — shredded an undiagnosed uterine leiomyosarcoma and sprayed malignant fragments across her peritoneal cavity, advancing a contained cancer to Stage IV. The tool marketed as the enabler of fast, scarless gynecology had, in her case, converted a survivable tumor into a terminal one.

The mechanism was inherent, not incidental. No reliable preoperative test distinguishes a benign fibroid from an occult uterine sarcoma; both present as a uterine mass, and the blade cannot tell them apart. When the FDA ran the numbers in April 2014, it estimated that roughly 1 in 350 women undergoing hysterectomy or myomectomy for presumed fibroids in fact harbored an unsuspected sarcoma, and that morcellating such a tumor risked peritoneal dissemination and upstaging to FIGO Stage III or IV in approximately 25 to 65 percent of cases — sharply cutting long-term survival. The device had been in routine American use since 1993, cleared through the FDA’s 510(k) pathway as “substantially equivalent” to predicate devices, never required to show it would not seed cancer.

The reckoning came not from regulators or manufacturers but from a patient and her husband. Reed and Dr. Hooman Noorchashm, a cardiothoracic surgeon, filed her adverse-event report in December 2013 and launched a relentless public campaign. A 2017 Government Accountability Office review (GAO-17-231) found that across the device’s first two decades the FDA had received essentially no adverse-event reports linking morcellators to cancer spread — a real, recurring harm invisible to a passive surveillance system dependent on clinicians voluntarily reporting it. The FDA issued its first safety communication on April 17, 2014, J&J withdrew its market-leading devices, and on November 24, 2014, the agency mandated a boxed warning. Amy Reed died on May 24, 2017, at 44.